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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, TaiwanBackground: Administration of an exogenous surfactant may affect both ventilatory and hemo-
dynamic parameters in preterm infants with respiratory distress syndrome (RDS). Peripheral
perfusion may be expected to be influenced, and serial perfusion index (PI) values may show
this effect. Noninvasive transcutaneous carbon monoxide (TCO) monitoring may show RDS
severity, oxidative and inflammatory stress, and response to surfactant treatment.
Methods: This randomized controlled nonblinded study was performed in 30 preterm infants
with RDS, treated with poractant alfa (n Z 15) or beractant (n Z 15); 18 preterm infants
without RDS served as a control group. Oxygenation and hemodynamic parameters were re-
corded and compared through the first 6 hours of treatment. PI and TCO values were measured
prior to (Tp), immediately after (T0), and at 5 minutes (T5), 30 minutes (T30), 60 minutes (T60),
and 360 minutes (T360) after the bolus surfactant administration. The mean arterial pressure,
oxygenation index, pH, and lactate levels were recorded simultaneously.
Results: Both study groups had lower Tp PI and higher Tp TCO levels than controls. Both surfac-
tant preparations improved the PI, TCO, mean arterial pressure, oxygenation index, pH, and
lactate levels at the end point of T360. However, the median Tp PI value of 1.3 first decreased
to 0.86 at T0 (P < 0.001), and then it increased to 0.99 at T5 (p < 0.001) and to 1.25 at T30
(p Z 0.037). The median Tp TCO value of 3 decreased to 2, 1.5, 0, and 0 at T0, T5, T30, and
T60, respectively (p < 0.001). PI more quickly recovered to Tp values (30 minutes vs. 60Recent Advances in Neonatal Medicine, October 2e4, 2011.
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Perfusion index in respiratory distress syndrome 249minutes) and reached the control group values (30 minutes vs. 360 minutes) with beractant
compared to that with poractant alfa. TCO recovered to Tp values in both groups at the same
time (5 minutes vs. 5 minutes), but reached the control group values more quickly (5 minutes
vs. 30 minutes) with poractant alfa than with beractant.
Conclusion: Patients with RDS had poor perfusion, and PI improved with both surfactant prep-
arations only following a short decline in the 1st minute. The expected improvement of PI
occurred earlier in the beractant subgroup. TCO declined in both groups, showing lung
improvement and decreased oxidative/inflammatory stress, and it was normalized earlier with
poractant alfa.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Respiratory distress syndrome (RDS) is a major cause of
mortality and morbidity in preterm infants due to insuffi-
cient surfactant production. Exogenous surfactant therapy
significantly reduces ventilatory parameters and oxygen
requirements, improves lung function during the acute
course of RDS in preterm infants, and reduces neonatal
mortality.1e4
Pulse oximeters have recently become essential in-
struments at neonatal intensive care units to monitor the
oxygen saturation (SpO2). Recent advances in new-
generation pulse oximetry technology have made it
possible to measure the peripheral perfusion index (PI) and
transcutaneous carbon monoxide (TCO) levels continuously.
The PI, which is derived from the pulse oximeter signal,
reflects real-time changes in the peripheral blood flow and
indicates adequacy of peripheral perfusion.5e8 A low PI
value indicates poor perfusion and predicts severe illness in
newborn infants. Cresi et al9 reported PI values of 0.9, 1.2,
and 1.3 on Days 1, 3, and 7 of life, respectively, in clinically
and hemodynamically stable preterm neonates. De Felice
et al10 reported significantly lower PI values (0.86  0.26 vs.
2.02  0.7) in newborns with poor peripheral perfusion.
Oxidative stress and inflammation are related to
increased carbon monoxide (CO) production, which also
correlates with TCO levels.11e13 In patients with pneu-
monia, higher carboxyhemoglobin and exhaled CO levels at
the onset of illness decrease to the levels observed in
healthy controls after antibiotic treatment.14 End-tidal CO
levels are elevated in preterm infants developing bron-
chopulmonary dysplasia (BPD), which is associated with an
early inflammatory response; therefore, end-tidal CO
measurement has been suggested as a predictor of BPD.15
Although exogenous surfactant administration is a life-
saving treatment, its bolus administration may have some
deleterious effects. Tissue oxygenation, hemodynamic pa-
rameters, and peripheral perfusion may change during and
after bolus exogenous surfactant administration. However,
there are limited data about peripheral perfusion and CO
production changes after surfactant treatment.
In this study, we aimed to compare PI and TCO changes,
together with oxygenation and ventilator parameters, prior
to and after administration of two different natural exog-
enous surfactant preparations.2. Materials and methods2.1. Patients
Thirty preterm neonates, born between 26 and 36 weeks of
gestation and receiving early surfactant administration for
RDS at the neonatal intensive care unit of Ege University
Children’s Hospital between 2011 and 2012, were included
in this study after the receipt of informed parental consent.
Eighteen healthy preterm infants who did not require any
oxygen or CPAP treatment were enrolled in the control
group. The study was approved by the local ethics com-
mittee (no.: 12-1/18, 20.02.2012).
Perinatal and neonatal data were collected. The exclu-
sion criteria were as follows: structural cyanotic congenital
heart disease, hemodynamically significant patent ductus
arteriosus, congenital pneumonia, pulmonary malforma-
tion, clinical chorioamnionitis, early sepsis and unstable
infants in need of inotropic support, severe birth asphyxia,
and major congenital anomalies. All study patients with
clinical and radiological signs of severe RDS were intubated
with uncuffed endotracheal tubes, without any obvious
leakage around the tube, and ventilated using a time- and
pressure-controlled ventilator (Babylog 8000; Draeger,
Luebeck, Germany).
Exogenous surfactant therapy was administered as
described in the European Consensus Guidelines and by the
American Academy of Pediatrics.16,17
Preparations of 200 mg/kg poractant alfa (Curosurf;
Cheise Pharmaceuticals, Parma, Italy) (n Z 15) or 100 mg/
kg beractant (Survanta; Abbott Laboratories, Chicago, IL,
USA) (n Z 15) were randomly administered into the endo-
tracheal tube within the first 2 hours of life. Indications of
surfactant administration were an alveolar/arterial SpO2
ratio of <0.22, an FiO2 of >0.4, and an oxygenation index
(OI) of >7. During the procedure, the tube was discon-
nected from the ventilator and calculated surfactant doses
were given according to the manufacturer’s guidelines,
followed by 2 minutes of manual ventilation. The endo-
tracheal tube was then reconnected, and the physician
(D.T.) observed the infant for 30e60 seconds until the SpO2
reached >90% on a pulse oximeter. Thereafter, the peak
inspiratory pressure of the ventilator was reduced by 1e2
cmH2O at each attempt.
Figure 1 PI and TCO changes in (A) the whole study group and (B) the beractant and poractant alfa subgroups. The parameters
were assessed prior to surfactant administration (pretreatment, Tp) and at 0 minute (T0), 5 minutes (T5), 30 minutes (T30), 60
minutes (T60), and 360 minutes (T360) after surfactant administration. The dashed lines in all four graphics demonstrate the median
value of healthy preterm infants (control level). * Significantly different compared to Tp. PI Z perfusion index; RPCL Z point at
which the control level was reached; TCO Z transcutaneous carbon monoxide.
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2.2.1. Devices
The PI, heart rate (HR), TCO, and SpO2 measurements were
carried out using a Masimo Rainbow Radical SET-7 (Masimo
Corporation, Irvine, CA, USA) pulse oximeter. In the pulse
oximeter, a constant amount of light is absorbed by the
skin, other tissues, and nonpulsatile blood, whereas a var-
iable amount of light is absorbed by the pulsating arterial
inflow. The PI is a scalar value derived from the magnitude
of the pulsations displayed on the plethysmographic
waveform. It is calculated as the ratio of the pulsatile
component to the nonpulsatile component of the infrared
signal returning from the monitoring site, and it reflects the
ratio of the pulsatile component to the nonpulsatile
component of the bloodstream. For the pulse oximeter
used here, the upper and lower PI limits reported by the
manufacturer were 0.02% and 20.00%, respectively.
The Masimo pulse oximeter measures SpO2 and TCO in
arterial blood continuously and noninvasively, relying onthe same basic principles of pulse oximetry (spectropho-
tometry) to make its TCO measurement. For the pulse ox-
imeter used here, the upper and lower TCO limits reported
by the manufacturer were 0% and 40%, respectively.
Since ambient light may affect oximeter operation, the
probes were wrapped in an opaque material. The sensor
was placed preductally in the right hand. The systolic
pressure, diastolic pressure, and mean arterial pressure
(MAP) were measured indirectly using an oscillometric de-
vice (Infinity Delta Monitor; Draeger).
2.2.2. Timing of measurements
The PI and TCO values, as well as HR, MAP, body temper-
ature, SpO2, and OI, were assessed at different time points
such as prior to treatment (i.e., prior to surfactant
administration) (Tp), right after the completion of surfac-
tant administration and manual ventilation (T0), and at 5
minutes (T5), 30 minutes (T30), 60 minutes (T60), and 360
minutes (T360) after surfactant administration. Blood gas
and lactate analysis was performed at Tp, T30, T60, and T360.
Table 1 Demographic characteristics of the control and study groups.
Control group (n Z 18) Study group (n Z 30) p
Gestational age (wk) (mean  SD) (minemax) 30.5  3.5 (25e35) 29.8  3.1 (23e36) 0.05 (NS)
Birth weight (g) (mean  SD) (minemax) 1641.4  426.3 (810e2630) 1396.7  671.7 (450e2600) 0.05 (NS)
Sex (male/female) 9/9 14/16 0.06 (NS)
Apgar score at 1 min (mean  SD) (minemax) 6.6  1.3 (4e9) 4.6  2.0 (3e8) 0.001
Apgar score at 5 min (mean  SD) (minemax) 7.5  0.7 (5e9) 6.8  1.2 (5e9) 0.05 (NS)
PPROM (%) 26.7 16.7 0.33 (NS)
Antenatal corticosteroid (%) 80 72 0.39 (NS)
NS Z not significant; PPROM Z preterm premature rupture of membranes; SD Z standard deviation.
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Infants in the control group were also evaluated for vital
signs, together with PI and TCO measurements, during the
first 6 hours of life for comparison with the study group.
2.2.4. Comparison of the control and study groups
Thirty preterm infants with RDS [treated with either por-
actant alfa (n Z 15) or beractant (n Z 15)] comprised the
study group, and 18 preterm infants without RDS, the
control group. The study and control groups were compared
with respect to initial PI and TCO values.
The point at which the control level was reached, while
comparing the levels of measurements, is shown in
Figure 1.
2.2.5. Statistical analysis
Statistical analysis was performed using SPSS 15.0 for Win-
dows. The data are summarized as percentages,
means  standard deviation, or median and interquartile
ranges, where appropriate. With skewed numerical data,
differences were assessed by Friedman analysis of vari-
ance, followed by Wilcoxon’s rank sum test if a significant
difference was found. The ManneWhitney U test was used
for comparison of independent groups. For normally
distributed consecutive data, an analysis of variance was
performed, followed by Bonferroni’s test if there was a
significant difference between the groups. Student t test
was used to compare paired or independent groups in
normally distributed data. In all analyses, p < 0.05 was
considered to indicate statistical significance.
3. Results
3.1. Demographic characteristics
All 30 [16 female (53.3%) and 14 male (46.6%)] preterm
neonates enrolled in the study completed the trial. Table 1
shows the demographic data and clinical characteristics of
the control and study groups.
3.1.1. Changes in vital characteristics and blood gases in
study patients
There were no changes in the HR or body temperature at
Tp, T0, T5, T30, T60, or T360 (p > 0.05). The MAP values
remained within normal levels throughout the study. The
lowest MAP value of 37.0  9.5 was observed at T0 and thehighest MAP value of 41.2  10.4 at T60 (p Z 0.02) (Table
2).
Arterial blood gas analysis showed that the Tp PO2 of
48  15 Torr (48.7  15.5 mmHg) increased significantly to
66  27 Torr (66.3  27 mmHg) at T60 (p Z 0.001) and
69  24 Torr (69.2  24.5 mmHg) at T360 (p Z 0.001). The
mean Tp lactate value of 2.25  1.09 decreased to
1.74  0.86 at T60 (p Z 0.001) and 1.62  0.62 at T360
(pZ 0.001), while the mean Tp pH of 7.27  0.08 increased
to 7.30  0.08 at T60 (p Z 0.005) and 7.31  0.07 at T360
(p Z 0.005) (Table 2).
The mean Tp FiO2 (fraction of inspired oxygen) of
68.87  22.7% decreased significantly to 45.1  25.3% at T60
(pZ 0.001) and 43.1  20.3% at T360 (pZ 0.001). The OIs at
T60 and T360 were significantly lower than the Tp level
(p < 0.001) (Table 2).
3.1.2. Changes in serial PI and TCO measurements in the
study and control groups
3.1.2.1. PI values
3.1.2.1.1. Study group. The median PI value of Tp 1.3
decreased significantly to 0.86 at T0, and then increased
significantly to 0.99 at T5 and to 1.25 at T30 (p < 0.001,
p < 0.001, and p < 0.001, respectively). The PI value at T60
(1.45) was similar to and that at T360 (1.6) was higher than
the Tp PI value (1.3) (p Z 0.03) (Table 2).
In the control group, the median Tp PI value of 2.1 was
significantly higher than the study group median Tp PI of 1.3
and PI values at T0, T5, and T30, but it was similar to the PI
values at T60 (p Z 0.06) and T360 (p Z 0.17) (Figure 1).
3.1.2.2. TCO values. The study group median Tp TCO
value of 3 decreased significantly to 2 at T0, to 1.5 at T5,
and to 0 at T30, T60, and T360 (p < 0.001) (Table 2).
The study group median TCO values at Tp (3), T0 (2), and
T5 [1.5 (3)] were significantly higher than the control group
median TCO value of 0.0 (1) (p < 0.001, p < 0.001, and
p Z 0.02, respectively). The study group median TCO
values at T30 of 0 (2), T60 of 0 (1), and T360 of 0 (1) were
similar to the control group median TCO values (Figure 1).
3.1.3. Changes in serial PI and TCO measurements in the
beractant and poractant alfa study subgroups
The beractant and poractant alfa subgroups did not differ
significantly with respect to sex, gestational age, birth
weight, frequency of preterm membrane rupture, fre-
quency of tocolysis, antenatal corticosteroid
Table 2 Cardiorespiratory physiology evaluation in the study group prior to and after surfactant administration.
Time (min)
Tp T0 T5 T30 T60 T360 P*
PIy 1.3 (1.3)
(0.5e5.3)
0.86 (0.9)z
(0.3e4)
0.99 (0.9)z
(0.4e4.2)
1.25 (0.9)z
(0.4e3)
1.45 (1.2)
(0.5e3.7)
1.6 (1.1)z
(0.78e4)
0.001
TCOy 3 (3)
(0e11)
2 (3)z
(0e9)
1.5 (3)z
(0e9)
0 (2)z
(0e7)
0 (1)z
(0e4)
0 (1)z
(0e4)
0.001
SpO2 (%)
y 96 (7)
(73e100)
93 (6)
(72e100)
94.5 (5)
(75e100)
97 (4)z
(73e100)
96 (5)
(77e100)
94.5 (5)
(76e100)
0.04
OIy 12.2 (6.7)
(8e48)
x x 11.2 (6.0)
(8e44)
5.35 (7.3)z
(2e38)
4.55 (7.5)z
(2e36)
0.001
pHjj 7.27  0.08
(7.1e7.5)
x x 7.28  0.06
(7.1e7.3)
7.30  0.08z
(7.1e7.5)
7.31  0.07z
(7.2e7.5)
0.005
Lactate (mmol/L) jj 2.25  1.09
(1e5.9)
x x 2.20  1.06
(0.9e5.2)
1.74  0.86z
(0.6e5.3)
1.62  0.62z
(0.5e5.0)
0.001
Heart rate (bpm)jj 146.4  18.3
(101e188)
144.7  18.5
(104e188)
145.5  16.5
(117e183)
147.6  15.8
(117e177)
148.4  14.5
(114e179)
146.6  12.6
(105e188)
0.43 (NS)
Body temperature (C) jj 37.1  0.3
(36.6e37.6)
37.2  0.2
(36.6e37.4)
37.1  0.4
(36.5e37.7)
37.0  0.1
(36.7e37.4)
37.1  0.2
(36.8e37.4)
37.1  0.1
(36.5e37.5)
0.56 (NS)
MAP (mmHg) jj 39.0  11
(26e63)
37.0  9.5
(23e62)
37.7  9.7
(25e62)
39.0  9.3
(25e62)
41.2  10.4
(27e67)
39.0  10.1
(24e63)
0.005
bpm Z beats per minute; MAP Z mean arterial pressure; NS Z not significant; OI Z oxygenation index; PI Z perfusion index;
SD Z standard deviation; SpO2 Z oxygen saturation; TCO Z transcutaneous carbon monoxide.
* A linear mixed model for repeated measures was used to assess the time course of the measurements in all infants.
y The data are presented as the median (interquartile range) and minimum and maximum values.
z p < 0.05 versus Tp.
x Not tested in the blood gas analysis.
jj The data are presented as means  SD and minimum and maximum values.
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and T360 (p > 0.05) (Figure 1, and Tables 3 and 4).
The study subgroup median PI levels reached the median
PI value of the control group at T30 with beractant, but at
T360 with poractant alfa. Infants treated with beractant
reached the median Tp PI level at 30 minutes, while it took
60 minutes in those treated with poractant alfa (Figure 1
and Table 4).
The study subgroup TCO levels reached the control
group median TCO value at T30 with beractant, but at T5
with poractant alfa. Both preparations decreased the TCO
value to the Tp value at 5 minutes (p Z 0.002).
The beractant and poractant alfa groups did not differ
significantly with respect to the rates of intraventricular
hemorrhage (p Z 0.28), periventricular leukomalacia
(pZ 0.50), BPD (pZ 0.76), and mortality (pZ 0.38) (Table
3). No acute ventilator problems, which may be associated
with surfactant administration, such as pneumothorax
occurred in the study group or the control group.
4. Discussion
Our study showed similar positive effects of both surfactant
preparations on lung functions, and, for the first time in the
literature, it also showed that preterm infants with severe
RDS had lower PI and higher TCO levels than control infants.
After surfactant administration, a rapid PI decline at the 1st
minute was followed by an increase in PI levels, reaching
normal values at 30 minutes with beractant and at 60 mi-
nutes with poractant alfa. Both exogenous surfactantpreparations similarly improved lung function and
decreased TCO levels, reaching normal values at 5 minutes
with poractant and at 30 minutes with beractant.
The use of animal-derived and synthetic surfactants in
RDS treatment has been extensively evaluated for their
effects on oxygenation and ventilator parameters in pre-
term infants.18,19 Treatment with a double dose of por-
actant alfa (200 mg/kg) is associated with rapid weaning of
oxygen and ventilatory pressures, fewer additional doses,
cost benefits, and a survival advantage in comparison with
beractant or calfactant.19 In the present study, beractant
and double-dose poractant alfa were randomly used, and
both surfactant preparations significantly increased the PO2
levels and decreased FiO2 requirements and OI. However,
there were no significant differences between the two
surfactant regimens with regard to blood gas parameters
(pH, lactate level, and PO2) and FiO2; there were also no
significant differences in terms of mortality and morbidity
(BPD, intraventricular hemorrhage, and periventricular
leukomalacia) between the groups (Table 3).
Although the effects of different surfactant preparations
on blood pressure, cardiac output, HR, peripheral vascular
resistance, arterial oxygen levels, cerebral perfusion, and
oxygenation have been investigated extensively, there are
no studies evaluating the association of changes in TCO
values and PI with bolus surfactant administration.
Some infants may show transient cyanosis and brady-
cardia following bolus surfactant instillation.16,18e20 Sur-
factant instillation was followed by a rapid decrease in MAP
and cerebral blood flow in animals21 and in clinical
Table 3 Comparison of the demographic data for the two surfactant-treated groups.
Beractant (n Z 15) Poractant alfa (n Z 15) p
Gestational age (wk) (mean  SD) (minemax) 30.1  3.7 (23e36) 29.07  2.1 (26e32) 0.354 (NS)
Birth weight (g) (mean  SD) (minemax) 1635.1  773.3 (650e2600) 1157.4  461.5 (450-1830) 0.05 (NS)
Sex (male/female) 8/7 6/9 0.66 (NS)
PPROM (%) 33.3 20 0.68 (NS)
Tocolysis (%) 26.6 33.3 0.50 (NS)
IVH (%) 6.6 20 0.28 (NS)
PVL (%) 13.3 6.6 0.50 (NS)
BPD (%) 26.6 26.6 0.76 (NS)
Mortality (%) 20 26.6 0.65 (NS)
BPD Z bronchopulmonary dysplasia; IVH Z intraventricular hemorrhage; PPROM Z preterm premature rupture of membranes;
PVL Z periventricular leukomalacia; SD Z standard deviation.
Perfusion index in respiratory distress syndrome 253studies.22,23 Schipper et al12 reported significant decreases
in MAP, HR, cerebral blood flow, and FiO2 after bolus sur-
factant administration in 12 premature infants with RDS.
Roll et al23 assessed changes during surfactant adminis-
tration, and found short-term but significant decreases in
both HR and SpO2. One to three minutes after surfactant
administration, HR, SpO2, and transcutaneous PO2
increased significantly with an increase in cerebral
oxygenation. In the present study, immediately after bolus
surfactant administrations, there were only insignificant
decreases in HR and SpO2 at T0 compared to those at Tp in
both subgroups (Tables 2 and 4).
The Tp PI value was significantly higher in the controls
than in the RDS group, indicating clinical severity and poor
perfusion in the RDS group. In the RDS group, with surfac-
tant administration, the median Tp PI of 1.3 (1.3) decreased
to 0.86 (0.9) at T0, but it later increased significantly at T5
and reached the baseline (Tp PI) level at T60. The Tp and
post-treatment body temperature, and HR did not differ
significantly. The MAP decreased at T0 and then increased,
showing a significant difference between the values at T0Table 4 PI, TCO, and OI prior to and after beractant and porac
Tp T0 T5
Beractant PI 1.4 (1.5)
(0.5e5.3)
0.82 (0.9)z
(0.3e4)
1.2 (
(0.4e
TCO 4 (3)
(0e11)
3 (3)x
(0e9)
2 (3)
(0e9
OI 11.7 (3.8)
(8e38)
jj jj
Poractant alfa PI 1.3 (1.3)
(0.5e3.8)
0.9 (1.1)x
(0.4e2.5)
0.98
(0.5e
TCO 3 (6)
(0e11)
2 (3)x
(0e8)
1 (2)
(0e4
OI 14 (11.7)
(8e48)
jj jj
OI Z oxygenation index; PI Z perfusion index; TCO Z transcutaneou
* The data are presented as the median (interquartile range) and m
y A linear mixed model for repeated measures was used to assess t
z p < 0.05 vs. Tp.
x p < 0.05 vs. Tp.
jj Not tested in the blood gas analysis.and T60. Significantly different PI values indicated perfusion
changes throughout the procedure and healing process.
These findings can be explained by the initially negative
effects of the surfactant on the MAP and peripheral
perfusion, which recovered at 60 minutes after surfactant
administration. The PI reached the baseline level at 30
minutes in the beractant group but at 60 minutes in the
poractant group (Figure 1 and Table 4). However, PI
reached the control group values within 30 minutes in the
beractant group but within 360 minutes in the poractant
group, indicating the therapeutic efficacy of the surfactant
on hemodynamics. Our data showed that surfactant ther-
apy caused an initial decline in peripheral perfusion within
the 1st minute after administration, which may have been
due to the invasive nature of the procedure, causing a short
period of hypoxia.
CO is a product of endogenous metabolic processes, and
its presence in exhaled breath fluctuates with systemic,
pulmonary, or airway inflammation.15,24 Exhaled CO is
correlated with arterial CO and TCO in different age
groups.25,26tant alfa administration.*
Time (min)
T30 T60 T360 p
y
1.1)z
2.8)
1.5 (1.1)
(0.4e3)
1.7 (1.4)
(0.5e3.7)
1.6 (1.4)
(0.8e4)
0.001
x
)
0 (2)x
(0e7)
0 (1)x
(0e4)
0 (1)
(0e2)
0.001
10.7 (3.3)
(8e33)
4.3 (3.9)x
(2e28)
4 (3.5)x
(2e26)
0.001
(1)x
3.2)
1.2 (0.9)x
(0.7e3.0)
1.4 (1)
(0.5e3.2)
1.6 (1)x
(1e3.3)
0.001
x
)
0 (1)x
(0e3)
0 (1)x
(0e3)
0 (1.2)x
(0e2)
0.001
13 (10.7)
(8e42)
6.4 (8.1)x
(2.2e38)
5.2 (7.8)x
(2e36)
0.001
s carbon monoxide.
inimum and maximum values.
he time course of the measurements in all infants.
254 D. Terek et alUnder normal physiologic conditions, CO is produced by
the oxidative degradation of heme, and diffuses from the
blood to the alveolar air. Oxidative stress and inflammation
may increase CO production through increased expression
of heme oxygenase-1, depending on the availability of
heme and nonenzymatic lipid peroxidation.11,13,14,27,28 RDS
is also associated with pulmonary inflammation and may
induce upregulation of pro- and anti-inflammatory cyto-
kines, leading to increases in CO production.13,27 In patients
with pneumonia, increased exhaled CO levels decrease
with antibiotherapy.14
Krediet et al28 suggested that early (1st week) high end-
tidal CO measurements corrected for inhaled CO in RDS
patients may predict BPD. In the present study, the Tp TCO
levels were significantly higher in the RDS group than in the
control group; however, a rapid decrease occurred after
surfactant treatment. Although both surfactant prepara-
tions rapidly improved the TCO, the poractant group
reached the control group values at 5 minutes, which took
30 minutes in the beractant group. The continuous decline
in TCO was probably due to the positive effects of surfac-
tant on pulmonary function together with its anti-
inflammatory effect.
This study was limited by the small number of patients in
each surfactant preparation group. However, this is the first
study to compare serial PI and TCO measurements after
surfactant administration with a control group and also to
compare the effects of different surfactant preparations. A
second strength of this study is that measurements were
obtained carefully by the same pediatrician (D.T.).
In conclusion, preterm infants with severe RDS had lower
PI and higher TCO levels than control infants, and surfac-
tant administration improved peripheral perfusion, lung
disease, and oxidative and inflammatory stress. Noninva-
sive monitoring of PI and TCO as markers of peripheral
perfusion and lung function may be useful for follow-up of
these high-risk infants.
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